CBL0137 and NKG2A Blockade: A Novel Immuno-Oncology Combination Therapy for MYC-Overexpressing Triple-Negative Breast Cancers

Medicine, Oncology, Life Sciences, Immunology,
Triple-negative breast cancer   MYC overexpression   CBL0137   NKG2A blockade   Immunotherapy   Tumor microenvironment   Immune suppression  

Academic Background and Problem Statement Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer, accounting for 15-20% of all breast cancer cases. Due to the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), TNBC is insensitive to hormone the...

Generation of Allogeneic CAR-NKT Cells from Hematopoietic Stem and Progenitor Cells Using a Clinically Guided Culture Method

Medicine, Rheumatology and Immunology, Hematology, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
Allogeneic CAR-NKT cells   Hematopoietic stem cells   Immunotherapy   Clinical culture method   Tumor microenvironment  

Generation of Clinically Applicable CAR-NKT Cells Research Background Chimeric Antigen Receptor (CAR) T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of B-cell malignancies and multiple myeloma. However, the use of autologous CAR-T cell products presents challenges such as high costs, long manufacturing ...

The Role of SDCBP in Immunotherapy of Colorectal Cancer

Medicine, Rheumatology and Immunology, Oncology, Life Sciences, Cell Biology, Immunology,
Colorectal cancer   Immunotherapy   Tumor microenvironment   Anti-PD1 therapy   SDCBP   Zinc pyrithione  

Role of Syndecan Binding Protein (SDCBP) in Regulating Tumor Microenvironment, Tumor Progression, and Anti-PD1 Efficacy in Colorectal Cancer Background In recent years, immunotherapy has brought revolutionary advancements in cancer treatment. However, for colorectal cancer (CRC), anti-programmed cell death 1 (APD1) therapy shows relatively limited ...